Monash University

Embargoed and Restricted Access

Reason: Under embargo until April 2019. After this date a copy can be supplied under Section 51(2) of the Australian Copyright Act 1968 by submitting a document delivery request through your library

The Economics of Funding New Cancer Drugs

posted on 2018-01-16, 03:17 authored by TATJANA ELSBETH MACLEOD
This thesis presents an economic analysis of factors influencing HTA drug funding decision-making for "high-cost" cancer drugs. Four research questions are considered. Literature review identifies the factors prioritized by payers, public and patients in funding decision-making for new cancer drugs. An empirical analysis then identifies the factors prioritized by Scotland in decision-making. The third empirical analysis applies survival analysis to identifies factors which increase or decrease time to a positive recommendation. The final analyses test if uptake of Risk Sharing Agreements significantly increases access to publicly-funded cancer drugs, and identifies the conditions which facilitate a Risk-sharing agreement.


Campus location


Principal supervisor

Anthony Harris

Additional supervisor 1

Jeff Richardson

Year of Award


Department, School or Centre

Centre for Health Economics

Additional Institution or Organisation

Center for Health Economics


Doctor of Philosophy

Degree Type



Faculty of Business and Economics